Asia-Pacific Regenerative Medicines Market by Product (Cell-Based & Acellular Products), Therapy (Cell Therapy, Gene Therapy, Tissue Engineering), and Application (Orthopedic, Dermatology, Cardiovascular) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)
Asia-Pacific Regenerative Medicines Market by Product (Cell-Based & Acellular Products), Therapy (Cell Therapy, Gene Therapy, Tissue Engineering), and Application (Orthopedic, Dermatology, Cardiovascular) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis and Forecasts (2016 to 2021)
ID: 277 | Pages: 140 | September 2016 | Region: Asia Pacific
Asia-Pacific regenerative medicines market is expected to reach USD 10.71 billion by 2021 from USD 3.01 billion in 2016, growing at a CAGR of 28.90% during the forecast period 2016-2021. Regenerative medicines repair, replace or regenerate human cells, tissues, or organs affected due to injury, disease, aging processes, congenital defects, and damage due to trauma. These medicines restore normal functions of cells & tissues. These medicines are available in different types such as genes, somatic cells, stem cells, and other types. Some of these medicines (such as stem cells) have the ability to proliferate, differentiate thereby restore the original structure of cells or tissues or organs. Regenerative medicines are used in varied range of degenerative disorders include cardiovascular, neurodegenerative diseases, dermatology, and orthopedic, among others. Majority of the researchers aim to focus on the development of innovative technologies to provide better regenerative medicines and effective healthcare treatment solutions to patients.
Government initiatives supporting advanced therapies, rising focus of foreign pharmaceutical companies to invest on Asian healthcare industry, growing number of patients suffering from chronic disease conditions, and increasing demand for organ transplantation are driving the growth of regenerative medicines market in Asia-Pacific region. However, scarcity of skilled professionals, poor penetration rate of advanced healthcare treatment solutions, and difficulties to maintain the regenerative medicines, and requirement of high budget for the development of cell based products (such as stem cells) are restraining the growth of regenerative medicines market in Asia-Pacific region.
Asia-Pacific regenerative medicines market is segmented based on product, therapy, and application. Based on product, the market is further sub-segmented as cell-based products and acellular products. Of these, cell-based products segment is estimated to account for larger share of Asia-Pacific regenerative medicines market by product in 2016. Further, Cell-based products segment is classified as autologous and allogeneic products. Based on therapy, the market is segmented as cell therapy, gene therapy, tissue engineering, and immunotherapy. Of these, cell therapy is estimated to command the highest share of Asia-Pacific regenerative medicines market by therapy in 2016.
Based on application, the market is segmented as orthopedic & musculoskeletal spine, dermatology, central nervous system, cardiovascular, oncology, diabetes, and other applications. Among these, orthopedic & musculoskeletal spine is estimated to command the largest share of Asia-Pacific regenerative medicines market by application in 2016.
On the basis of geographical areas, Asia-Pacific regenerative medicines market is segmented as Japan, China, India, Australia, and South Korea.
The key players in regenerative medicines market such as, Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.), and Mesoblast Ltd. (Australia).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Product
5.2.1 Introduction
5.2.2 Cell-Based Products
5.2.2.1 Autologous Cell-Based Products
5.2.2.2 Allogeneic Cell-Based Products
5.2.3 Acellular Products
5.3 Therapy
5.3.1 Introduction
5.3.2 Cell Therapy
5.3.3 Gene Therapy
5.3.4 Tissue Engineering
5.3.5 Immunotherapy
5.4 Application
5.4.1 Introduction
5.4.2 Orthopedic & Musculoskeletal Spine
5.4.3 Dermatology
5.4.4 Cardiovascular
5.4.5 Central Nervous System
5.4.6 Oncology
5.4.7 Diabetes
5.4.8 Other Applications
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 South Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Vertex Pharmaceuticals Incorporated (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Acelity L.P. Inc. (U.S.)
8.3 Celgene Corporation (U.S.)
8.4 StemCells, Inc. (U.S.)
8.5 Organogenesis Inc. (U.S.)
8.6 NuVasive, Inc. (U.S.)
8.7 Vericel Corporation (Genzyme) (U.S.)
8.8 Cytori Therapeutics Inc. (U.S.)
8.9 Advantagene, Inc. (U.S.)
8.10 Mesoblast Ltd. (Australia)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
- Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
- Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
- Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
- Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
- A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
- Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
- An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
- Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
| Title | Price | Add To Cart |
- Asia-Pacific Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Regenerative Medicines Market By Product, From 2016-2021 (USD Billion)
- Asia-Pacific Cell-Based Products Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Acellular Products Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Regenerative Medicines Market By Therapy, From 2016-2021 (USD Billion)
- Asia-Pacific Cell Therapy Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Gene Therapy Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Tissue Engineering Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Immunotherapy Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Regenerative Medicines Market By Application, From 2016-2021 (USD Billion)
- Asia-Pacific Orthopedic & Musculoskeletal Spine Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Dermatology Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Cardiovascular Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Central Nervous System Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Oncology Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Diabetes Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Other Applications of Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- China Regenerative Medicines Market By Product, From 2016-2021 (USD Billion)
- China Regenerative Medicines Market By Therapy, From 2016-2021 (USD Billion)
- China Regenerative Medicines Market By Application, From 2016-2021 (USD Billion)
- India Regenerative Medicines Market By Product, From 2016-2021 (USD Billion)
- India Regenerative Medicines Market By Therapy, From 2016-2021 (USD Billion)
- India Regenerative Medicines Market By Application, From 2016-2021 (USD Billion)
- Japan Regenerative Medicines Market By Product, From 2016-2021 (USD Billion)
- Japan Regenerative Medicines Market By Therapy, From 2016-2021 (USD Billion)
- Japan Regenerative Medicines Market By Application, From 2016-2021 (USD Billion)
- South Korea Regenerative Medicines Market By Product, From 2016-2021 (USD Billion)
- South Korea Regenerative Medicines Market By Therapy, From 2016-2021 (USD Billion)
- South Korea Regenerative Medicines Market By Application, From 2016-2021 (USD Billion)
- Australia Regenerative Medicines Market By Product, From 2016-2021 (USD Billion)
- Australia Regenerative Medicines Market By Therapy, From 2016-2021 (USD Billion)
- Australia Regenerative Medicines Market By Application, From 2016-2021 (USD Billion)
- Asia-Pacific Cell-Based Products Regenerative Medicines Market By Type, From 2016-2021 (USD Billion)
- Asia-Pacific Autologous Cell-Based Products Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- Asia-Pacific Allogeneic Cell-Based Products Regenerative Medicines Market By Region, From 2016-2021 (USD Billion)
- China Cell-Based Products Regenerative Medicines Market By Type, From 2016-2021 (USD Billion)
- India Cell-Based Products Regenerative Medicines Market By Type, From 2016-2021 (USD Billion)
- Japan Cell-Based Products Regenerative Medicines Market By Type, From 2016-2021 (USD Billion)
- South Korea Cell-Based Products Regenerative Medicines Market By Type, From 2016-2021 (USD Billion)
- Australia Cell-Based Products Regenerative Medicines Market By Type, From 2016-2021 (USD Billion)
Licence Type 
Clients
Why buy reports from Market Data Forecast
Free Customization
Free report customization that helps you gain required information for always being one step ahead of the competition
Post Purchase Support
6 months of post purchase support via email and phone; serving your needs 24x7 and helping you troubleshoot any technical issues
Best Price guaranteed
Customer focused research services and expertly devised strategic analyses made into premium quality reports at lowest prices
Insightful Snapshots
Summarized overviews of entire reports into customized presentations to ascertain market estimations and driving forces at a quick glance